Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients
Disease-free survival (DFS) rates according to the preoperative serum interleukin-6 (IL-6) status. (a) DFS of all 207 patients who underwent curative resection. (b) DFS of 188 patients with stages I–III colorectal cancer. (c) DFS of the 60 stage II patients.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.